BioNTech Announces Closing of $512 Million Underwritten Offering of American Depositary Shares

    NEXT STORY
    Zentalis Pharmaceuticals Announces Proposed Public Offering of Common Stock
    PREV STORY
    Chiasma Announces 48-Week Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA® in Patients with Acromegaly
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    New Phase 2 Patient Data Presented at ASCO Strengthen the Evidence for Anti-Tumor Activity of VB-111 in Recurrent GBM

    TEL AVIV, Israel, June 05, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), today announced ...

    author_avatar
    NASDAQ Market News

    BELLUS Health Announces Positive Top-Line Phase 1 Results for its Chronic Cough Drug Candidate BLU-5937

    - No Taste Loss at the Anticipated Therapeutic Doses - - BLU-5937 is Shown ...

    author_avatar
    NASDAQ Market News

    ImCheck Therapeutics Expands Leadership Team with Appointment of Hans Henrik Chrois Christensen as Chief Financial Officer and Chief Operating Officer

    author_avatar
    NASDAQ Market News